Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) — PREOPANC-5

Borderline Resectable Pancreatic Cancer Clinical Trial

Official title:
Neoadjuvant Triple Treatment With FOLFIRINOX Plus Pembrolizumab and SABR in Patients With Borderline Resectable Pancreatic Cancer (PREOPANC-5): A Multicenter Single Arm Phase I/II Trial of the Dutch Pancreatic Cancer Group

Status Not yet recruiting

Clinical Trial Summary

Since patients with borderline resectable pancreatic cancer (BRPC) have a limited life expectancy, it is important to improve treatment strategies. Therefore, the objective of this study is to investigate whether neoadjuvant triple treatment chemotherapy, immunotherapy and radiotherapy, followed by surgery and chemotherapy and immunotherapy survival in patients with BRPC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Borderline Resectable Pancreatic Cancer
Pancreatic Neoplasms

Clinical Trial Details

NCT number	NCT06384560
Study type	Interventional
Source	Amsterdam UMC, location VUmc
Contact	J. W. Wilmink, MD, PhD
Phone	+31 204444321
Email	j.w.wilmink@amsterdamumc.nl
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	May 2024
Completion date	March 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04617821` - AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer	Phase 3
Suspended	`NCT04090463` - IORT on Borderline Resectable Pancreatic Cancer	Phase 2
Terminated	`NCT04698915` - Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer	Phase 2
Recruiting	`NCT03850769` - Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT03443921` - Divestment for Artery-involved Pancreatic Cancer	N/A
Recruiting	`NCT06345300` - NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study	Phase 2
Active, not recruiting	`NCT02717091` - Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer	Phase 2
Terminated	`NCT02241551` - Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT06387810` - Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer	Phase 2
Recruiting	`NCT04855331` - Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC	N/A